Developing Anti-TIGIT Antibodies to Enhance the Body's Response to Cancer

Tanya Keenan, MD, MPH, is an executive director in the oncology clinical development group at Merck Research Laboratories. Dr Keenan is the clinical lead for the asset development team for the anti-TIGIT antibody vibostolimab, currently being evaluated in multiple phase 3 studies. She graduated from the University of Pittsburgh and then earned an MD from the University of Pennsylvania and an MPH from the Johns Hopkins Bloomberg School of Public Health. She completed her internal medicine residency at Massachusetts General Hospital, where she later served as chief resident. Dr Keenan then completed her oncology fellowship with a focus in breast cancer at Dana-Farber Cancer Institute, during which she collaborated on early phase immunotherapy studies and conducted computational analyses of clinical genomic data. She has worked on multiple preclinical programs and global phase 1/2 trials in advanced solid tumors.